FOLH1 and neoplasm: The efficacy of anti-PSMA antibodies as radiotherapeutic carriersis in part boosted by the rapid internalization of the PSMA-boundantibody complex, enhancing payload delivery to achieve high %ID/gand residualizing the radiation within the tumor. However, at high radiation doses, the long circulationtime of antibodies can lead to exposure of the bone marrow that canresult in myelosuppression and hematologic toxicity, which representsthe primary dose-limiting toxicity for these therapies.